Axsome Resolves All SUNOSI Patent Litigation, Securing Exclusivity Until 2040
Summary
Axsome Therapeutics has settled all patent litigation for its drug SUNOSI, ensuring market exclusivity until at least March 2040 and removing a key legal overhang.
Key Events
-
Patent Litigation Resolved
Axsome Therapeutics has settled all outstanding patent litigation related to its product SUNOSI (solriamfetol) with generic applicants.
-
Generic Entry Date Set
Generic versions of SUNOSI can be sold starting on or after March 1, 2040, or September 1, 2040, if pediatric exclusivity is granted.
-
Long-Term Exclusivity Secured
The settlement provides Axsome with market exclusivity for SUNOSI for at least another 14 years, protecting future revenue streams.
-
Regulatory Review
The settlement agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
Analysis
This settlement removes significant legal uncertainty surrounding Axsome's key product, SUNOSI. By granting generic entry no earlier than 2040, Axsome secures a long period of market exclusivity, protecting a substantial revenue stream and providing long-term clarity for investors. This de-risks a major product, especially as the stock is trading near its 52-week high.
At the time of this filing, AXSM was trading at $231.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4B. The 52-week trading range was $96.09 to $238.56. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.